Trinity Biotech is developing a new continuous glucose monitor called CGM+. Instead of focusing only on glucose, the wearable uses proprietary needle-free sensor technology that could allow for expanded tracking from a single modular wearable device. Future versions could track heart signals, sleep, movement, and temperature. Trinity’s CEO John Gillard says “CGM+ is not just a device—it’s a proprietary data engine we are building for the AI health ecosystem.”

So far, only the glucose tracking has been tested, with detailed results expected soon. A pre-pivotal trial confirmed 15-day wear without the need for fingerstick calibrations. CGM+ uses fewer disposable parts thanks to its reusable applicator which could mean lower cost and better sustainability than competitors.

Trinity says CGM+ is meant to grow into a platform, not just a sensor. Which means down the line, CGMs could shift from single-purpose diabetes tools to full-on health hubs.

Trinity is not alone in developing a multi-analyze sensor—SAVA is developing its own needle-free CGM that could measures a list of vitals and Abbott is working on a dual glucose-ketone sensor it already has insulin pump partners for.

Trinity Biotech plans to submit it to the FDA in 2026 and launch later that year. Whether this makes it to consumers or not, I expect exciting days ahead for the future of CGMs.

Disclaimer: Diabetech content is not medical advice—it’s for educational purposes only. Always consult with a physician before making changes to your healthcare.